...
search icon
ikt-img

Inhibikase Therapeutics Inc, Common Stock

IKT

NAQ

$2.35

+$0.12

(5.38%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$163.00M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
122.46K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.12
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.12 L
$4.2 H
$2.35

About Inhibikase Therapeutics Inc, Common Stock

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIKTSectorS&P500
1-Week Return--0.03%1.53%
1-Month Return-11.65%4.56%4.75%
3-Month Return-0.42%1.29%2.77%
6-Month Return80.77%-3.54%12.18%
1-Year Return-7.48%1.59%22.34%
3-Year Return-67.36%13.55%38.91%
5-Year Return-96.04%40.85%80.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.12M698.47K3.10M123.44K260.50K[{"date":"2019-12-31","value":36.21,"profit":true},{"date":"2020-12-31","value":22.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.98,"profit":true},{"date":"2023-12-31","value":8.4,"profit":true}]
Cost of Revenue2.55M893.80K11.36M6.72K13.62M[{"date":"2019-12-31","value":18.74,"profit":true},{"date":"2020-12-31","value":6.56,"profit":true},{"date":"2021-12-31","value":83.41,"profit":true},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(1.43M)698.47K3.10M116.72K(13.36M)[{"date":"2019-12-31","value":-46.12,"profit":false},{"date":"2020-12-31","value":22.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.76,"profit":true},{"date":"2023-12-31","value":-430.81,"profit":false}]
Gross Margin(127.36%)100.00%100.00%94.55%(5127.77%)[{"date":"2019-12-31","value":-127.36,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.55,"profit":true},{"date":"2023-12-31","value":-5127.77,"profit":false}]
Operating Expenses5.70M2.82M14.77M18.13M6.73M[{"date":"2019-12-31","value":31.43,"profit":true},{"date":"2020-12-31","value":15.55,"profit":true},{"date":"2021-12-31","value":81.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.13,"profit":true}]
Operating Income(5.70M)(2.82M)(14.77M)(18.13M)(20.09M)[{"date":"2019-12-31","value":-569814800,"profit":false},{"date":"2020-12-31","value":-281849200,"profit":false},{"date":"2021-12-31","value":-1476614000,"profit":false},{"date":"2022-12-31","value":-1812860800,"profit":false},{"date":"2023-12-31","value":-2008979200,"profit":false}]
Total Non-Operating Income/Expense(49.67K)(58.80K)(39.85K)148.91K1.95M[{"date":"2019-12-31","value":-2.54,"profit":false},{"date":"2020-12-31","value":-3.01,"profit":false},{"date":"2021-12-31","value":-2.04,"profit":false},{"date":"2022-12-31","value":7.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(5.72M)(2.85M)(14.79M)(18.05M)(19.03M)[{"date":"2019-12-31","value":-572298300,"profit":false},{"date":"2020-12-31","value":-284789400,"profit":false},{"date":"2021-12-31","value":-1478606300,"profit":false},{"date":"2022-12-31","value":-1805415500,"profit":false},{"date":"2023-12-31","value":-1902888300,"profit":false}]
Income Taxes24.84K29.40K19.92K(148.91K)(148.91K)[{"date":"2019-12-31","value":84.47,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":67.76,"profit":true},{"date":"2022-12-31","value":-506.45,"profit":false},{"date":"2023-12-31","value":-506.45,"profit":false}]
Income After Taxes(5.75M)(2.88M)(14.81M)(17.91M)(18.88M)[{"date":"2019-12-31","value":-574781800,"profit":false},{"date":"2020-12-31","value":-287729600,"profit":false},{"date":"2021-12-31","value":-1480598600,"profit":false},{"date":"2022-12-31","value":-1790524900,"profit":false},{"date":"2023-12-31","value":-1887997700,"profit":false}]
Income From Continuous Operations(5.72M)(2.85M)(14.79M)(18.05M)(19.13M)[{"date":"2019-12-31","value":-572298300,"profit":false},{"date":"2020-12-31","value":-284789400,"profit":false},{"date":"2021-12-31","value":-1478606300,"profit":false},{"date":"2022-12-31","value":-1805415500,"profit":false},{"date":"2023-12-31","value":-1912999500,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(5.75M)(2.88M)(14.81M)(17.91M)(19.03M)[{"date":"2019-12-31","value":-574781800,"profit":false},{"date":"2020-12-31","value":-287729600,"profit":false},{"date":"2021-12-31","value":-1480598600,"profit":false},{"date":"2022-12-31","value":-1790524900,"profit":false},{"date":"2023-12-31","value":-1902888300,"profit":false}]
EPS (Diluted)(0.55)(0.41)(0.86)(0.72)(2.77)[{"date":"2019-12-31","value":-55.42,"profit":false},{"date":"2020-12-31","value":-41.16,"profit":false},{"date":"2021-12-31","value":-86,"profit":false},{"date":"2022-12-31","value":-72,"profit":false},{"date":"2023-12-31","value":-277,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IKT
Cash Ratio 0.66
Current Ratio 0.85

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IKT
ROA (LTM) -112.68%
ROE (LTM) -270.10%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IKT
Debt Ratio Lower is generally better. Negative is bad. 1.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.12

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IKT
Trailing PE NM
Forward PE NM
P/S (TTM) 1000000.00
P/B 26.46
Price/FCF NM
EV/R 2.75
EV/Ebitda 0.34

FAQs

What is Inhibikase Therapeutics Inc share price today?

Inhibikase Therapeutics Inc (IKT) share price today is $2.35

Can Indians buy Inhibikase Therapeutics Inc shares?

Yes, Indians can buy shares of Inhibikase Therapeutics Inc (IKT) on Vested. To buy Inhibikase Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IKT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Inhibikase Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Inhibikase Therapeutics Inc (IKT) via the Vested app. You can start investing in Inhibikase Therapeutics Inc (IKT) with a minimum investment of $1.

How to invest in Inhibikase Therapeutics Inc shares from India?

You can invest in shares of Inhibikase Therapeutics Inc (IKT) via Vested in three simple steps:

  • Click on Sign Up or Invest in IKT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Inhibikase Therapeutics Inc shares
What is Inhibikase Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Inhibikase Therapeutics Inc (IKT) is $4.2. The 52-week low price of Inhibikase Therapeutics Inc (IKT) is $1.12.

What is Inhibikase Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Inhibikase Therapeutics Inc (IKT) is 26.46

What is the Market Cap of Inhibikase Therapeutics Inc?

The market capitalization of Inhibikase Therapeutics Inc (IKT) is $163.00M

What is Inhibikase Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Inhibikase Therapeutics Inc is IKT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top